Filing Flows

Filing Flows › Ultralife (ULBI) › Q3 2026

Ultralife (ULBI) Q3 2026 earnings results (third quarter 2026)

10-Q filed Nov 5, 2026

Ultralife (ULBI) reported revenue of $48.3M for the third quarter 2026 (Q3 2026), +11% from a year earlier and +0.7% from the quarter before. Operating margin was 6.6%, net earnings $2.4M (4.9% of revenue).

Revenue$48.3M
Year over year+11%
Quarter over quarter+0.7%
Operating margin6.6%
Net earnings$2.4M

Ultralife, Q3 2026: revenue $48.3M (+11% year over year), operating margin 6.6%, net earnings $2.4M, operating cash flow −$2.9M. The chart follows the revenue to costs, profit and cash.

Q3 2026AmountQ/QY/Y
Revenue$48.3M+0.7%+11%
Gross profit$13.3M-4%+38%
Operating profit$3.2M-7%—
Net earnings$2.4M-5%—
Operating cash flow−$2.9M-347%-1580%

What changed

Revenue was $48.3M in Q3 2026, up 11% year over year and up 1% from the previous quarter. Battery & Energy Products Segment was the largest line at 93% of revenue. Battery & Energy Products Segment added $5.1M year over year (up 13%), 105% of the total change. Communications Systems Segment declined 7%.

Gross margin was 27.5%, up 5.4 points from Q3 2025. Operating profit was $3.2M, a 6.6% margin (up 8.8 points year over year). Operating expenses fell 4% while revenue rose 11%. The fastest-growing cost line was Research & development (+12%). Net earnings were $2.4M. The effective tax rate was 13.2%.

Operating cash flow was −$2.9M. Non-cash charges added back $1.4M of depreciation and amortization and $92K of share-based compensation. Working capital and other items used $6.8M. Capital expenditures of $591K exceeded it, leaving free cash flow of −$3.5M.

Questions

What was Ultralife's revenue in the third quarter 2026?

Ultralife (ULBI) reported revenue of $48.3M for the third quarter 2026 (Q3 2026), +11% from a year earlier and +0.7% from the quarter before.

Was Ultralife profitable in the third quarter 2026?

Operating profit was $3.2M (6.6% of revenue) and net earnings $2.4M.

Open the interactive Sankey →

Source: Ultralife 10-Q on SEC EDGAR.